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Abstract Last week I looked through some of the earlier records of the hospital where you, Sir, and I and most of us here had our training. You may like to know that the interest in ischaemic heart disease which Lauder Brunton established 100 years ago is being actively perpetuated in the same ward. The area where we established the first major Coronary Care Unit in Britain a year ago is very probably the same as that where young Brunton made his classical observation concerning the use of nitride of amyl.  Prevention of ischaemic heart disease, whether we are considering angina or myocardial infarction, must be taken to mean the prevention of the premature onset of the disease. Death from a heart attack at an advanced age would not necessarily seem undesirable. 
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IS ANGINA PREVENTABLE?
M. F. Oliver
Department of Cardiology, Royal Infirmary, Edinburgh
L a st w eek I looked th rou gh  som e o f  the earlier 
records o f  the hospital w here yo u , Sir, and  I and 
m ost o f  us here h ad  o u r train in g. Y o u  m a y  like 
to kn ow  th at the interest in ischaem ic heart 
disease w h ich  L a u d e r  B runton  established 100 
years a go  is bein g  a c tiv e ly  p erp etu ated  in  the 
sam e w ard . T h e  a re a  w here w e  established the 
first m ajor C o ro n a ry  C a re  U n it  in  B rita in  a  y ea r 
ago  is ve ry  p ro b a b ly  the sam e as that w here y o u n g  
B runton  m ad e his classical observation  con cern ­
in g  the use o f  n itride o f  am yl.
P reven tion  o f  ischaem ic h eart disease, w hether 
w e are  con siderin g a n g in a  or m yo ca rd ia l in ­
farction , m ust be taken  to m ean  the p revention  
o f  the premature onset o f  the disease. D e a th  from  a 
h eart a tta ck  a t an  a d va n ced  age  w ou ld  not 
necessarily seem undesirable.
In terven tion  can  be exp ected  to produce the 
highest y ie ld  i f  it  is m ad e  before sum ptom s o f 
ischaem ic h eart disease develop. T h a t  w e should 
d irect o u r atten tion  p a rticu la rly  tow ards the 
p re-sym ptom atic stage o f  the disease is em ph a­
sized b y  consideration  o f  the im m ediate m ortality  
fo llow in g acu te  m yo ca rd ia l in farction . It  has 
been show n b y  B ainton  an d  Peterson (1963) and 
b y  K a n n e l et al (1963) th at the m ajority  o f  
patients w ho d ie  after their first m yo card ia l 
in farct do so w ith in  an  h our o f  the onset o f  
sym ptom s. T h u s, m a n y  victim s never reach 
hospital an d  the m o rta lity  from  acu te  heart 
a ttacks is con siderably  under-estim ated from  
hospital statistics. T h ese  reports h igh ligh t the 
need to p reven t the a tta ck  from  o ccu rrin g  in  the 
first instance, and  in  this talk I do not propose to 
consider w h at can  be don e a b ou t the prevention 
o f  a n g in a  once a  p atien t has developed m yo ­
card ia l in farction . T h is  is usually  kn ow n  as 
secon dary prevention.
A  far m ore interesting and  fun dam en tal ch a l­
lenge is -  W h a t can  be done tow ards the p rim ary 
p revention  o f  a n g in a  an d  other presentations o f
ischaem ic heart disease ? Professor M o rris has 
a lrea d y  outlined w ith  g rea t c la rity  the p rin cipal 
risk factors associated w ith  the d evelop m en t of 
ischaem ic heart disease, and  I propose n ow  to 
return  to these an d  consider w h ich  are am en ab le  
to control and p revention  (T a b le  I on p age  44).
Control o f  risk factors
H yp erlip id aem ia  is m ostly co n tro llab le , either 
b y  the use o f  A tro m id -S  o r a  p olyu n satu rated  
fa tty  acid  diet an d  I w ill consider the con trol o f 
this risk factor in m ore detail shortly. It  m a y  also 
be p artly  p reven table  insofar as a  rap id  increase 
in w eigh t is p reventable  an d  this is often associ­
ated  w ith  h yp ertriglyceridaem ia.
T h e  control o f  hypertension presents a  m ajor 
p roblem  w hich  is outside the scope o f  this talk. 
In  the first p lace  it  is b y  no m eans certain , b e ­
cause o f  the unsatisfactory n ature o f  the a va ila b le  
drugs, that hypertension can  alw ays be co n trolled  
an d  certain ly  the side effects o f  these drugs are 
sufficiently serious to p reclude their w idesp read  
use as a  m eans o f  con trol o f  m oderate h yp erten ­
sion in  otherw ise h ealth y m en. In  the second 
p lace, it  has not been show n that a d eq u a te  co n ­
trol even o f  severe hypertension  is associated 
w ith  few er m yo card ia l infarcts w h en  com parison 
is m ade w ith  patients w hose hypertension  has not 
been a d eq u a tely  con trolled  (H o d ge et al., 19 6 1; 
H o o d  el al., 1963). T h e  p rin cipal reasons for 
reduction  o f  overall m o rta lity  w hen  hypertension  
is con trolled  are that there are few er deaths from  
cerebrovascular accidents an d  from  congestive 
failure, b u t there is no sign ifican t ch an ge in  the 
in ciden ce o f  deaths from  ischaem ic h eart disease.
W h ile  m ost o f  the rem arks w h ich  I am  m akin g 
a p p ly  e q u a lly  to m yo card ia l in farction  as to 
angina, it  is w orth  stressing that the p attern  o f  
cigarette  sm oking in  patients w ith  a n g in a  pectoris 
is quite d ifferent from  that w h ich  one obtains 
from  patients w ith  m yo ca rd ia l in farction.
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T A B L E  I
RISK FACTORS IN ISCHAEMIC HEART DISEASE 
AND THEIR CONTROL
Well documented risk factors
Hyperlipidaemia
Hypertension
Cigarette smoking
Surgical or irradiation menopause
Less well documented influences 
Physical inactivity 
A  rapid gain in weight 
Diabetes mellitus |
Hyperuricaemia /
Thrombogenic tendency 1 
Psychogenic stress j
controllable, partly preventable 
partly controllable, seldom preventable 
preventable 
often preventable
preventable
preventable
partly controllable, not preventable 
not controllable, not preventable
T A B L E  II
SMOKING HABITS IN 118 WOMEN UNDER 45 YEARS WITH 
CONFIRMED ISCHAEMIC HEART DISEASE
Nos. of smokers and cigarettes
day
Total No. of non-
numbers smokers 1- 14 15-24 25 +
A.P. 58 23 21 l3 1
M .I. 60 8 27 18 7
Comparison of non-smokers with heavy smokers (15  or more) indicates a significant difference between
A.P. and M .I. (0-005 > P > 0 -00i).
T A B L E  I I I
SMOKING HABITS IN 118 WOMEN UNDER 45 YEARS WITH CONFIRMED 
ISCHAEMIC HEART DISEASE
Per cent who are 
non-smokers
Per cent who are cigarette smokers
1 - 14/day 15-24/day 25 +  /day
A .P. (58) 
U .K . pop­
40 36 22 2
ulation* 47 37 l3 3
M .I. (60) i3 45 30 12
*M ean figure for women 2 1-3 5  and 36-55 derived from 1961 report o f Tobacco Manufacturers Com­
mittee.
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Professor Morris has already mentioned the experi­
ence o f the Fram ingham  study and I will only add 
to this by commenting that Doyle et al., (1964) 
also showed a clear-cut relationship between 
heavy cigarette smoking and m yocardial in- 
farction in the A lban y study but no such relation- 
ship existed between heavy cigarette smoking and 
angina. In Tables II  and III , you will see similar 
findings in young women. D uring the last 15 
years, I have seen 150 women, all under the age 
o f 45 with symptoms suggestive o f  ischaemic 
heart disease; 58 o f these had angina pectoris with 
m yocardial ischaemia in their electrocardiograms 
and 60 had m yocardial infarction. Examination 
of these tables indicates that women who get a 
m yocardial infarct have different cigarette smok­
ing habits from women who develop angina 
pectoris and also from women in the normal U .K . 
population. Various suggestions have been put 
forward for this difference. It is possible, although 
there is no good factual evidence, that cigarette 
smoking leads to a thrombogenic tendency. There 
m ay be a greater degree o f coronary vasocon­
striction, perhaps coronary spasm as described by 
Dr. Gorlin and as a result there m ay be less 
satisfactory formation o f coronary collateral ves­
sels in heavy cigarette smokers. A  third possibility 
is that there are more arrhythmias in heavy 
cigarette smokers as a consequence o f increased 
catecholamine and free fatty acid production; in 
this context, it would be interesting to try to 
document whether there is a higher incidence o f 
sudden death and o f immediate m ortality 
following myocardial infarction in heavy cigarette 
smokers compared with non-smokers. O ne o f the 
reasons for spending a little time considering 
cigarette smoking is that it may present a different 
problem so far as primary prevention is concerned 
when compared with the other risk factors which 
are perhaps more closely associated with the 
gradual development o f coronary atherosclerosis.
There is a higher than usual incidence of 
angina pectoris and m yocardial infarction in 
women whose reproductive life has ceased at an 
unduly early age. W hile a number o f these 
women undergo premature hormonely-deter- 
mined cessation of menstruation, surgery or 
irradiation are not uncommon causes. T he 
removal o f both ovaries, or their irradiation, can 
often be prevented.
Amongst the less well documented influences 
described in T able I, there are two which are in
theory entirely preventable. O ne is physical in­
activity and the other is rapid gain in weight. T he 
effects o f preventing physical inactivity on the 
development o f ischaemic heart disease have not 
been studied and there is no current trial to 
determine whether increased activity has a 
primary protective effect. O f  course, this is a very 
difficult subject to study. It would be necessary 
to identify a large group o f physically inactive 
men and to take a randomized proportion o f these 
men and ensure that they became physically 
active consistently and continuously over a long 
period o f time. It would be equally necessary to 
be certain that the remaining randomized half 
continued to be physically inactive. I think that 
this is impossible to do in any culture.
It has been suggested (Heyden, 1964) that a 
rapid gain in weight is associated with an increase 
in serum triglycerides but, o f  course, there is no 
good evidence as yet that an increase in serum 
triglycerides alone is an adverse risk factor. O ne 
has to distinguish the increased risk which is 
known to occur in patients with hypercholesterol- 
aemia from that which has yet to be shown in 
patients with hypertriglyceridaemia. It is also 
important to emphasize at this point that obesity 
by itself is not to be incriminated as an indepen­
dent risk factor. In the Framingham and Albany 
surveys, obesity only becomes a significant adverse 
influence when it is associated with hyper- 
cholesterolaemia or hypertension. M y own ex­
perience in the small group o f young women 
already mentioned confirms this view. O n the 
other hand, obesity has been shown to increase 
the work o f the heart and should therefore be 
avoided.
Primary Prevention Trials
T h e question proposed by the title o f this talk -  
“ Is Angina Preventable?”  demands consideration 
of the principles o f primary prevention trials. 
Prevention o f atherosclerosis itself is the most 
important therapeutic challenge today and it is 
likely to remain so until more is known about the 
initiating pathogenic influences. Some progress 
could be made, however, if  preventive trials are 
established in groups o f men who can from 
existing evidence be regarded as having an in­
creased risk o f developing one of the symptom 
complexes o f atherosclerosis.
A n y trial o f a preventive treatment in healthy 
men raises certain ethical questions. Is one justi­
fied in altering the habits by drugs or by diet of
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m en w ho regard them selves as entirely healthy in 
the hope that they w ill be protected from  a disease 
w hich  they m ay not ever g e t?  W h ile  this view  
com m ands respect and is sometimes p u t forw ard 
against prevention trials, m any doctors feel that 
there is a  stronger m oral argum en t in  favour o f  
such trials. It is necessary, therefore, to exam ine 
the design o f  p rim ary prevention trials.
A  n um ber o f  risk factors have a lready been 
defined and discussed in detail. T h ere  can be 
two different and  independent approaches to the 
control o f  these Factors. O n e  is to control one 
factor at a  tim e an d  the other a  num ber o f  factors 
sim ultaneously. Sup p ort can  be advan ced  for both 
approaches. I f  it is assumed that there are four 
different risk factors am en able to control, satis­
factory control o f  three sim ultaneously m igh t lead 
to a  reduction  for the sake o f  the exam ple o f  30 per 
cent in  m ortality  from  ischaem ic heart disease. 
S im ilarly , successful control o f  the fourth factor 
alone m igh t also lead to a  reduction  o f  30 per cent 
in  m ortality. S ince the control o f  several factors 
sim ultaneously m igh t theoretically  neutralize the 
effect o f  con trollin g some singly -  for exam ple, 
the increase in w eigh t w hich  follows the cessation 
o f  cigarette sm oking -  it can be postulated that 
control o f  a  fourth factor m igh t lead to an  even 
sharper fall in the attack  rate. O n e  can  conclude, 
therefore, that the control o f  several factors 
sim ultaneously and o f one singly are both rational 
and accep table  approaches towards the im ple­
m entation o f  p rim ary prevention trials. Par 
excellence, hyp erlipidaem ia is the risk factor 
m ost suitable for control alone.
Control o f  hyperlipidaemia
T h e re  are various approaches w hich  can  be 
m ade tow ards the establishm ent o f  trials to 
control hyperlipidaem ia. Perhaps the most satis­
facto ry  is to identify those in dividuals in the 
norm al p opu lation  w ith  the highest risk, to 
random ize these and treat h a lf  o f  them. A n o th er 
possibility is to concentrate on those w ho have 
hyp erlipidaem ia together w ith  other high risk 
characteristics, such as a fam ily history o f  vascular 
disease and  for exam ple, to study the effects o f  
correctin g hyp erlipidaem ia in the brothers and 
sisters o f  yo u n g patients w ith  m yocardial in­
farction. A n o th er possibility, w hich  is less satis­
factory because it entails a  m am m oth trial, is to 
take the w hole o f  a  given  population, to ran dom ­
ize them  a ll and treat h a lf  o f  them.
For a n um ber o f  years, w e have been studying 
here in E d in b u rgh  various m eans o f  con trollin g 
h yperlipidaem ia. I have personally taken  the 
view  that a n y  m ajor chan ge in the usual d iet is 
not likely  to be a  p racticab le  app ro ach  to the 
control o f  ischaem ic heart disease. I do not believe 
even i f  it could be show n that a  fun dam en tal 
chan ge in the norm al diet reduces the attack  rate 
from  ischaem ic heart disease and this has not y et 
been show n, that the p u b lic  w ill p a y  a n y  m ore 
attention to these findings than they are presently 
doin g to the in controvertib le  evidence that c iga r­
ette sm oking is associated w ith  lun g can cer and 
ischaem ic heart disease. T h u s, we have addressed 
ourselves to the problem  o f  try in g  to find a m eans 
o f  con trollin g hyp erlipidaem ia w ith ou t alteration  
o f  the diet. W e have studied oestrogens and 
thyroid horm ones and rejected them  both because 
they are only p artly  effective or have in tolerable 
side effects, an d  d u rin g  the last six years have 
concentrated p articu larly  on studying an d  a p ­
praising the effects o f  A trom id-S  (Sym posium  on 
A trom id, 1963).
I do not w an t to take up tim e discussing 
A trom id-S  but there are three m ajor points 
w hich require  attention. T h e  first is that this 
d ru g reduces elevated serum  cholesterol levels and 
also elevated serum  triglycerides (O liver, 1962). 
T h e  second is that it leads to rem oval o f  choles­
terol and  lip id  deposits from  tissues; tuberous 
x an th om ata disappear (Borrie, 1964) and lip- 
aem ic exudates resolve in diabetics (C u llen  el al., 
1964). T h e  third and perhaps the most im portant 
p oin t is that the d ru g causes a  large  efflux o f  
neutral sterols in the faeces (A hrens, 1969). T hus, 
there is excellent circum stantial evidence that 
the d ru g not only  lowers serum  lipids an d  rem oves 
it from  the tissues but that it a ctu ally  prom otes 
loss o f  cholesterol from  the body -  evidence w hich 
is lackin g for diets con tain in g polyunsaturated 
fats.
The Edinburgh Primary Prevention Trial
I  have been so im pressed by the effect o f  
A trom id-S  that two years ago I decided to take 
the plun ge and  establish a  p rim ary prevention  
trial using A trom id-S  as a  m eans for con trollin g 
hyperlipidaem ia. T h is  trial is jo in tly  run b y  m y ­
self and Professor M orris, and w ith  the close 
collaboration  o f  D r. R . A . C u m m in g from  the 
Blood Transfusion Service. T h e  m ajority  o f  the 
m en p artic ipatin g  in this trial are b lood donors
and all are volunteers. T h e age o f the men is 
between 30 and 59 years.
T h e hypothesis which we are trying to test is 
that reduction o f elevated serum lipids in healthy 
men leads to a decrease in the incidence of 
ischaemic heart disease. I f  after five or six years 
o f study, we come out with a negative result, then 
I think this will in fact be a contribution since the 
air will be cleared, as it were, and presumably we 
can then disregard elevated serum lipid levels as a 
therapeutic problem. O n the othe hand, if  the 
trial ends with a positive result then I believe that 
we m ay be able to say for the first time that is- 
chaem aic heart disease can really be prevented.
T h e aim  which we have set ourselves is to show 
a 5 per cent reduction in m orbidity and mortality 
from ischaemic heart disease and at a 1 per cent 
significance level. In order to do this, it can be 
calculated that 80 infarcts are required in a 
control group and thus 40 infarcts in a treated 
group. It is difficult to be exactly certain about 
the annual attack rate in hyperlipidaemic men
in Britain but the Framingham figures probably 
apply and for men o f the age with which we are 
dealing this is 1 per cent per annum. Thus, we 
will need to study 8,000 men in a control group 
for one year or better still, in view o f the progres­
sion o f the disease, 2,000 men over a minimum 
period o f four years. T he treated group must o f 
course be the same size and thus the basic re- 
quirements for this study are 4,000 men and these 
have to be obtained from a population three times 
this size. This is because we are selecting hyper- 
lipidaemic men -  in other words, those above the 
top tertile. It is im portant to emphasize the m ag- 
nitude o f the trial and the fact that prim ary 
prevention trials cannot be undertaken with 
small numbers.
T h e design of the Edinburgh Ischaemic Heart 
Disease Prevention T rial is shown in Fig. I. 
O live oil is used as a placebo; it is a monoene 
without effect at the dosage given on serum lipid 
levels. As you can see, we have an additional 
group in our study. This is 2,000 men in a
EDINBURGH I.H.D. PRIMARY PREVENTION TRIAL
FIG. 1
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hypolipidaem ic group also receiving olive oil. 
This third group acts as an  additional control 
and also allows all the team to be blind so far as 
the selection o f men is concerned. Thus, i f  a man 
asks why he has been selected for the trial and 
inquires whether he has a high serum cholesterol 
level, we can honestly answer that we do not 
know since we are looking at both ends o f the 
“ cholesterol population” . I should add that none 
o f the team know which man is receiving Atromid- 
S or olive oil, and so we are twice blinded in this 
study.
A t present, 1,700 men have been enrolled from 
the Edinburgh area. W e hope to obtain 4,000 
men from this area but because o f the difficulty 
in getting these large numbers, we are shortly 
going to extend the trial to Prague and Budapest 
where the exact design o f this trial will be repli­
cated. T h e statistical analysis from all three 
centres will be m ade in Professor M orris’ D epart­
ment in London. The establishment o f this trial 
in two other countries m ay be o f particular value 
in testing the practicability o f its application in 
the future; i f  sim ilar results can be obtained from 
three separate cultures, then they are all the more 
significant and impressive.
A t present, there is little to say about our own 
study. Obviously, there are no results available. 
We have been delighted with the co-operation 
and interest o f the participants. Since it is possible 
to measure Atrom id-S blood levels, we know that 
we have a very high adherence to the treatment 
and we also know that we have achieved the 
expected reduction in serum lipids.
Conclusion
I shall end by returning to the question which I 
set myself, “ Is angina preventable?”  I do not 
know the answer to this and I do not think that 
anybody else does yet. T h e only w ay, in my 
opinion, o f  finding out the answer is to establish 
prim ary prevention trials o f the types which I 
have outlined.
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